Full chimerism in nonmyeloablative stem cell transplantation in a β-thalassemia major patient (clas 3 Lucarelli)

Bone Marrow Transplantation

Volumn 30, Issue 6, 2002, Pages 409-410

  Hongeng, S ^a   Chuansumrit, A ^a   Hathirat, P ^a   Rerkamnuaychoke, B ^a   Chaisiripoomkere, W ^a   Jootar, S ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

thalassemia major; Nonmyeloablative stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOSPORIN; DEFEROXAMINE; FLUDARABINE; HYDROXYUREA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CASE REPORT; DISEASE SEVERITY; FEMALE; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE IRRADIATION; MORTALITY; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL TRANSPLANTATION; THALASSEMIA MAJOR; TREATMENT OUTCOME; ADJUVANT THERAPY; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; METHODOLOGY;

BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RADIOTHERAPY, ADJUVANT; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 0036750101     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703655     Document Type: Article

References (7)

1. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med 1990; 322: 417-421.
2. Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494-3499.
3. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol 1999; 11: 87-95.
4. Spitzer TR, McAfee S, Sackstein R et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
5. Krishnamurti L, Blazar BR, Wagner JE et al. Bone marrow transplantation without myeloablation for sickle cell disease. New Engl J Med 2001; 344: 68.
6. Gaziev D, Polchi P, Lucarelli G et al. Second marrow transplant for graft failure in patients with thalassemia. Bone Marrow Transplant 1999; 24: 1299-1306.
7. Xun CQ, Thompson JS, Jennings CD et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.